Varex Imaging Corporation

Varex Imaging Corporation (VREX) Market Cap

Varex Imaging Corporation has a market capitalization of β€”.

No quote data available.

CEO: Sunny S. Sanyal

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2017-01-23

Website: https://www.vareximaging.com

Varex Imaging Corporation (VREX) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive range of X-ray imaging components. These include essential hardware like X-ray tubes, digital detectors, and high-voltage connectors, alongside sophisticated software solutions for image processing, 3D reconstruction, and computer-aided diagnostics. The segment also supplies critical ancillary devices such as collimators, generators, and automatic exposure control mechanisms. These medical products serve a wide spectrum of applications, from general diagnostic imaging like radiography and fluoroscopy, to specialized areas such as mammography, computed tomography (CT), cardiac procedures, dental imaging, and surgical applications. They are also vital for radiation therapy, oncology, and advanced computer-aided detection systems. The Industrial segment focuses on providing X-ray technology for security and industrial inspection. Its offerings include Linatron X-ray accelerators, X-ray tubes, digital detectors, and high-voltage connectors. These components are crucial for diverse applications such as airport security scanning, cargo screening at border crossings, and nondestructive testing across various industries. Varex distributes its products through multiple channels, including direct sales to end-users, partnerships with imaging system Original Equipment Manufacturers (OEMs), independent service providers, and a network of distributors. With a significant global footprint, the company maintains operations across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Established in 2016, Varex Imaging Corporation is headquartered in Salt Lake City, Utah.

Analyst Sentiment

80%
Strong Buy

From 5 Active Polls

1Y Forecast: $14.50

β–² +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$15

Median

$15

High Bound

$15

Average

$15

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$14.50
β–² +29.58% Upside
Low Target
$14.50
30% Risk
Median Target
$14.50
30% Mid
High Target
$14.50
30% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ VAREX IMAGING CORP (VREX) β€” Investment Overview

🧩 Business Model Overview

Varex Imaging Corp designs and manufactures high-performance imaging subsystems used in radiology and advanced imaging workflows across healthcare and multiple industrial/security end markets. The value chain is anchored in proprietary detector and imaging component technology (e.g., direct/indirect conversion detector platforms and related electronics), followed by application engineering, qualification, and integration into OEM systems.

Revenue is generated when Varex supplies detector modules and imaging solutions to customers (including major medical imaging OEMs and industrial imaging integrators), and through a recurring services/aftermarket component embedded in long customer lifecycles. Stickiness is driven by (1) installed-base replacement cycles, (2) the qualification burden required to approve new detector platforms, and (3) performance verification requirements in regulated and safety-critical imaging environments.

πŸ’° Revenue Streams & Monetisation Model

Monetisation is primarily a mix of:

  • Hardware/Systems revenue (transactional): detector products and imaging subsystems sold with OEM programs and industrial project cycles.
  • Aftermarket and service-oriented revenue (more recurring): replacement parts, upgrades, and support that benefit from long installed bases and multi-year equipment utilization.

The margin profile is typically supported by a combination of technology differentiation (higher value content per system), manufacturing learning curves, and product mix across detector platforms used in higher-demand modalities. Operating leverage can expand when volume rises without commensurate increases in fixed costsβ€”particularly important in a business with specialized engineering and precision manufacturing.

🧠 Competitive Advantages & Market Positioning

Varex’s competitive position rests on technical differentiation plus switching costs created by qualification and installed-base integration, rather than on brand-led demand.

  • Hard-to-replace technology and performance verification: Competing detectors must meet demanding signal quality, noise characteristics, reliability, and system-level compatibility. In medical and safety-critical imaging, qualification is non-trivial and slows migration.
  • Switching costs / integration lock-in: OEMs and customers typically develop platform acceptance around proven detector performance, calibration requirements, and support processesβ€”creating friction for competitors.
  • Scale and manufacturing know-how: Detector and electronics manufacturing require process control and yield discipline; experience and tooling contribute to cost and reliability advantages over time.
  • Embedded engineering capability: Application engineering and system integration capability increase the probability of long-duration program participation.

Competitive benchmarking (industry peers):

  • Teledyne Imaging Systems / Teledyne Dalsa (e.g., detector and imaging electronics): Strengths are in imaging detectors and measurement systems, with focus often aligned to specific modalities and defense/industrial needs.
  • Hamamatsu Photonics (detectors and photonics components): Broad detector capabilities and deep technology in photonics, competing where customers value component-level performance and optics/electronics integration.
  • PerkinElmer (imaging and life-science/industrial measurement ecosystems): Broad instrumentation reach with emphasis on life-science and specialty imaging/measurement applications.

Positioning contrast: Varex spans a broad detector and imaging component portfolio across medical, industrial, and security-adjacent applications, while many rivals exhibit heavier concentration in specific detector technologies or end-market segments. This diversification can improve resilience across program cycles, but the core moat still centers on detector performance, qualification credibility, and installed-base switching friction.

πŸš€ Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by durable demand for higher-quality imaging with lower operational burden, combined with ongoing equipment refresh cycles:

  • Digital imaging expansion and performance upgrades: Migration toward advanced detector architectures and workflow efficiency supports replacement demand and higher value-content per system.
  • Medical modality mix shift: Imaging-intensive care pathways and expanded access tend to increase installed-base utilization and drive upgrades.
  • Semiconductor and industrial inspection tailwinds: More complex manufacturing processes increase inspection and metrology requirements, supporting demand for high-precision imaging components.
  • Security screening modernization: Ongoing need for improved detection performance and throughput supports detector demand in screening and inspection systems.
  • Aftermarket and upgrade pathways: Long installed-base lifetimes create a structural base for replacement parts and technology refresh initiatives.

⚠ Risk Factors to Monitor

  • Technological disruption: Advances such as photon-counting or alternative detector architectures could alter competitive dynamics if customers accelerate platform transitions. The key question is whether Varex maintains qualification and performance leadership during technology shifts.
  • Customer capex cyclicality: Medical imaging OEM and industrial project cycles can pressure order patterns during economic slowdowns.
  • Supply chain and component constraints: Specialized materials, semiconductor components, and precision manufacturing inputs can drive cost volatility and lead-time risk.
  • Execution and program risk: Detector platforms require successful ramp-ups, yield performance, and meeting system-level specifications on schedule for OEM programs.
  • Regulatory and reimbursement impacts (healthcare-linked demand): Adoption rates can be influenced by reimbursement environments and procurement approvals.

πŸ“Š Valuation & Market View

Market valuation for companies in imaging hardware and specialized components typically hinges on expectations for:

  • Revenue durability vs. cyclicality: Evidence of stable program participation and meaningful aftermarket/upgrade contribution reduces perceived volatility.
  • Gross margin trajectory: Technology mix, manufacturing yield improvements, and operating leverage are key drivers.
  • Conversion of R&D into defensible platforms: Sustained product differentiation and qualification wins influence long-term multiple support.
  • Working-capital efficiency: Hardware businesses are sensitive to inventory and receivables dynamics, which can affect quality of earnings.

Investors commonly frame value via EV/EBITDA- or earnings-based approaches, with the multiple responding to margin sustainability and credible program-to-program continuity rather than short-term growth prints.

πŸ” Investment Takeaway

Varex’s long-term investment case is anchored in detector technology differentiation and switching costs created by qualification, integration, and installed-base replacement dynamics. While imaging end markets can be cyclical, the combination of performance-driven customer acceptance, manufacturing know-how, and multi-end-market exposure supports a durable platform for program participation and after-market monetisation. The principal debate for investors is whether next-generation detector technologies reinforce Varex’s qualification advantage or compress competitive differentiation.


⚠ AI-generated β€” informational only. Validate using filings before investing.

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-03

"VREX reported Q2’26 (ended 2026-04-03) revenue of $216.0M and net loss of $8.1M (EPS -$0.19). Revenue rose 3.1% QoQ ($209.6M in Q1’26) but declined 5.6% YoY versus $228.9M in Q4’25. Net income swung materially QoQ: profit of $2.3M in Q1’26 turned to a loss ($-8.1M), while YoY it deteriorated sharply from $12.2M profit in Q4’25 to a loss this quarter. Profitability has deteriorated in the latest quarter: net margin fell to -3.75% from +1.10% QoQ, and operating margin declined to 6.7% from 7.3% QoQ (still far below the strong Q4’25 operating margin of 8.6%). On cash flow, operating cash flow was -$1.5M and free cash flow was -$7.7M, a clear step down from Q1’26 (FCF -$26.8M) and especially from Q4’25 (+$2.3M). The balance sheet shows solid liquidity (cash & short-term investments $88.3M) and low leverage (total debt $46.3M, net cash position of ~$39M). Equity is stable around $474M. Shareholder returns appear strong: the stock is up 67.74% over the last 1 year, indicating strong capital appreciation (dividend paid $0; buybacks were minimal in the quarter)."

Revenue Growth

Fair

Revenue +3.1% QoQ ($209.6M to $216.0M) but -5.6% YoY vs Q4’25 ($228.9M to $216.0M), suggesting mild near-term stabilization with softer demand versus the prior-year strong period.

Profitability

Caution

Gross margin is roughly stable (33.6% vs 33.3% QoQ), but earnings deteriorated: net income moved from +$2.3M QoQ to -$8.1M, and net margin fell from +1.10% to -3.75%. Operating margin slipped to 6.7% from 7.3% QoQ.

Cash Flow Quality

Caution

Operating cash flow turned negative (-$1.5M) and free cash flow was -$7.7M this quarter (vs -$26.8M in Q1’26 and +$2.3M in Q4’25). Cash burn pressure is evident despite prior-quarter improvements.

Leverage & Balance Sheet

Good

Liquidity remains adequate (cash & ST investments $88.3M) with low leverage (total debt $46.3M) and net cash of ~$39M. Equity is stable at ~$488M total equity, supporting resilience.

Shareholder Returns

Strong

Strong 1-year price momentum: +67.74% 1y_change. Dividend yield is 0 and buybacks were modest (+$1.5M repurchased), so total shareholder return is driven primarily by capital appreciation.

Analyst Sentiment & Valuation

Fair

Street target consensus is $14.50 vs current price $12.01 (modest implied upside). Valuation metrics show negative earnings (P/E not meaningful), so the outlook appears sentiment-driven more than earnings-based in the near term.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Varex delivered Q2 FY26 revenue of $216M (+1% YoY) with non-GAAP EPS of $0.21 and 34% non-GAAP gross margin at the top of guidance. However, GAAP gross margin fell 240 bps YoY, and costs pressures are evident: memory-chip inflation raised detector input costs despite adequate procurement and buffer stock. Inventory rose to support cargo inspection acceptance activity and to pre-position raw materials for the India detector ramp, with management targeting $20M-$25M inventory reduction over the next six months. On balance sheet, Q2 included a meaningful capital structure action: debt refinancing reduced leverage and interest expense, with gross debt $351M and cash $88M at quarter end. Guidance for 3Q calls for revenue $210M-$225M and non-GAAP EPS $0.15-$0.30, while FY26 annual revenue is $860M-$880M and EPS $0.80-$1.00. Management remains optimistic on demand stability; the main uncertainties are cost/lead-time/macro-driven execution and India regulatory ramp timing.

AI IconGrowth Catalysts

  • CT momentum in Medical; CT and radiography exceeded 5-quarter sales trend in Q2
  • Photon counting momentum in Industrial driven by demand in food inspection services
  • Cargo security systems: continued implementation of previously booked orders and new bookings across multiple countries
  • Design-in pipeline expansion: increased OEM design-in discussions for new X-ray sources and detectors enabling recurring OEM projects
  • Advanced imaging shift: integrated solutions combining tubes, smart detectors, generators, and Nexus DR/Nexus DRF software to support AI-enabled workflows

Business Development

  • Photon counting OEM engagement: 2 CT OEM customers plus 8 additional medical imaging OEMs actively engaged in modalities beyond CT (CBCT, DR, breast imaging)
  • Cargo inspection deals: multiple new deals in multiple countries, including mobile inspection systems and car scanners (no customer names disclosed)

AI IconFinancial Highlights

  • Revenue: $216 million, within guidance range; total revenues +1% YoY (Medical +2%, Industrial +1%)
  • Non-GAAP gross margin: 34%, at high end of guidance; GAAP gross margin 34% down 240 bps YoY (per CFO)
  • Non-GAAP EPS: $0.21, in line with expectations; GAAP EPS loss $(0.19) (operating loss $14M GAAP; non-GAAP operating income $19M)
  • Operating expenses: $54M non-GAAP (up $3M YoY) vs guidance referenced by analyst; management cited earlier-than-planned R&D and industrial channel development spending
  • Tax: Q2 non-GAAP tax expense $419k; tax rate 5% driven by discrete items and reduced full-year effective tax rate expectation to ~20%
  • Micro-X mark-to-market: noncash charge $1.8M embedded in EPS/EBITDA/EBIT (not adjusted out), stated as about $0.04 EPS impact
  • Working capital: days sales outstanding decreased 2 days to 62; days inventory increased 6 to 220; days payable increased 10 to 61

AI IconCapital Funding

  • Completed debt refinancing in Q2: reduced outstanding debt and decreased annual interest expense (credit agreement closed; senior secured notes redeemed)
  • Cash: $88M at quarter end, down $37M vs Q1 2026; decrease primarily due to March refinancing
  • Gross debt: $351M; net debt after cash/marketable securities: $263M
  • Adjusted EBITDA: $27M (12% of sales); trailing 12-month adjusted EBITDA $118M; net debt leverage ~2.2x
  • No share repurchase amounts mentioned in transcript

AI IconStrategy & Ops

  • India detector factory: completed; ramp-up slow due to product-by-product regulatory approvals; utilization currently low; expects material utilization by year-end with a gross margin/OpEx headwind becoming a tailwind around ~60%-70% utilization
  • Second (tube) factory: facilitization/equipment move-in/validation runs ongoing; ramp expected toward beginning of next year
  • Inventory build rationale: increased cargo inspection units at customer sites (acceptance procedures), shifting raw materials to India for detector ramp-up, plus tariffs and memory chip inflation; management expects inventory to decline by targeting $20M-$25M reduction over remaining 6 months
  • Supply chain actions: diversified/s regionalized suppliers; redundancies cited as mitigating logistics/energy cost impacts

AI IconMarket Outlook

  • 3Q FY26 guidance: revenue $210M-$225M; non-GAAP EPS $0.15-$0.30; assumptions include non-GAAP gross margin 33%-34%, non-GAAP operating expenses ~ $54M, interest/other net $6M-$7M, tax rate ~23%, diluted shares ~42M
  • FY26 annual guidance (restarting annual): revenue $860M-$880M; non-GAAP EPS $0.80-$1.00
  • 2H FY26 expectation: revenue up ~3% YoY

AI IconRisks & Headwinds

  • Memory chip cost inflation impacting detector business: costs increased; management maintains procurement flexibility via advance buying/buffer stock and offsets with favorable mix to protect gross margin
  • Inventory normalization risk: temporary buildup tied to cargo inspection acceptance and India ramp-up; requires execution to reduce inventory by $20M-$25M in remaining 6 months
  • Limited demand-side macro impact observed, but management flags macro effects primarily on costs/material availability/lead times/logistics
  • Industrial lumpy timing: linear accelerator transitions in EMEA tied to prior large European customer order cadence; could create quarter-to-quarter volatility
  • Regulatory approval lag risk for India ramp due to product-by-product approvals

Q&A: Analyst Interest

  • India ramp capacity & margin tailwind: Management said the India detector factory is completed but ramp is slow because each medical product needs regulatory approvals. Utilization is currently low; they expect material utilization by year-end, hoping a headwind flips to a tailwind around 60%-70% utilization. Tubes ramp begins next year.
  • Inventory drivers & runoff plan: Management attributed higher inventory to cargo inspection units at customer sites awaiting acceptance, a shift of raw materials to India to support detector ramp, plus tariff/memory-chip-related inflation. For the remaining six months of FY, they expect inventory to decline and target $20M-$25M inventory reduction.
  • Microchip cost pressure, logistics exposure, and pricing power: Management stated only detector operations depend on memory chips; supply is available with buffer stock though costs rose. They reported minimal direct logistics exposure to Strait of Hormuz for their products. They described pricing power in unusual shortages and said renewal-based contracts enable passing increases when too unusual to absorb.

Sentiment: MIXED

Note: This summary was synthesized by AI from the VREX Q2 2026 (FY ended 2026-05-07 call) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
Β© 2026 Stock Market Info β€” Varex Imaging Corporation (VREX) Financial Profile